Design Therapeutics (DSGN) EBITDA Margin (2020)

Design Therapeutics (DSGN) reported EBITDA Margin of 11700.0% for Q4 2020, up 1.8% sequentially from 11915.0% in Q3 2020.

Design Therapeutics (DSGN) EBITDA Margin (2020) Analysis & Trends

Design Therapeutics (DSGN) has 1 years of EBITDA Margin data on file, last reported at 11700.0% in Q4 2020.

For the quarter ending Q4 2020, EBITDA Margin changed N/A year-over-year to 11700.0%; the trailing twelve-month figure through Dec 2020 stood at 3685.84% (changed N/A YoY), and the FY2020 full-year result was 3685.84%, changed N/A from the prior year.
EBITDA Margin climbed to 11700.0% in Q4 2020, from 11915.0% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 438.73% in Q1 2020 to a low of 11915.0% in Q3 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	16.51%
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	17.83%
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	30.35%
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Design Therapeutics	725.54 Mn	502.72 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	-11,700.00%
Sep 30, 2020	-11,915.00%
Jun 30, 2020	-4,719.35%
Mar 31, 2020	-438.73%